Meta-Analysis of the Prognostic and Clinical Value of Tumor-Associated Macrophages in Hepatocellular Carcinoma

References

• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. doi: 10.1002/hep.20933.
   PubMed Web of Science ®Google Scholar
• Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim. Biophys. Acta. 2016;(1):23–34. doi: 10.1016/j.bbcan.2015.06.009.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555.
   PubMed Web of Science ®Google Scholar
• Yeung OW, Lo CM, Ling CC, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J. Hepatol. 2015;62(3):607–616. doi: 10.1016/j.jhep.2014.10.029.
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. (1097-4180 (Electronic)).
   Google Scholar
• Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. (2072-6694 (Print)).
   Google Scholar
• Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. (1878-3686 (Electronic)).
   Google Scholar
• Lee J, French B, Morgan T, French SW. The liver is populated by a broad spectrum of markers for macrophages. In alcoholic hepatitis the macrophages are M1 and M2. Exp. Mol. Pathol. 2014;96(1):118–125. doi: 10.1016/j.yexmp.2013.09.004.
   PubMed Web of Science ®Google Scholar
• Chavez-Galan L, Olleros ML, Vesin D, Garcia I. Much more than M1 and M2 macrophages, there are also CD169(+) and TCR(+) macrophages. Front. Immunol. 2015;6(263):263doi: 10.3389/fimmu.2015.00263.
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54–67. doi: 10.1158/2159-8274.CD-10-0028.
   PubMed Web of Science ®Google Scholar
• Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010;10(1):112–1471. doi: 10.1186/1471-2407-10-112.
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Mitsunaga S, Kinoshita T, et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci. 2012;103(11):2012–2020. doi: 10.1111/j.1349-7006.2012.02411.x.
   PubMed Web of Science ®Google Scholar
• Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol. 2014;128(3):347–362. doi: 10.1007/s00401-014-1274-2.
   PubMed Web of Science ®Google Scholar
• Li YW, Qiu SJ, Fan J, et al. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J. Cancer Res. Clin. Oncol. 2009;135(3):439–449. doi: 10.1007/s00432-008-0469-0.
   PubMed Web of Science ®Google Scholar
• Yan W, Liu X, Ma H, et al. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut 2015;64(10):1593–1604. doi: 10.1136/gutjnl-2014-307671.
   PubMed Web of Science ®Google Scholar
• Kong LQ, Zhu XD, Xu HX, et al. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One. 2013;8(3):e59771. doi: 10.1371/journal.pone.0059771.
   PubMed Web of Science ®Google Scholar
• Shu QH, Ge YS, Ma HX, et al. Prognostic value of polarized macrophages in patients with hepatocellular carcinoma after curative resection. J. Cell Mol. Med. 2016;20(6):1024–1035. doi: 10.1111/jcmm.12787.
   PubMed Web of Science ®Google Scholar
• Zhou SL, Hu ZQ, Zhou ZJ, et al. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology 2016;63(5):1560–1575. doi: 10.1002/hep.28445.
   PubMed Web of Science ®Google Scholar
• Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum. Pathol. 2009;40(3):381–389. doi: 10.1016/j.humpath.2008.08.011.
   PubMed Web of Science ®Google Scholar
• Zhu XD, Zhang JB, Zhuang PY, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 2008;26(16):2707–2716. doi: 10.1200/JCO.2007.15.6521.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li JQ, Jiang ZZ, Li L, Wu Y, Zheng L. CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma. J. Pathol. 2016;239(2):231–241. doi: 10.1002/path.4720.
   PubMed Web of Science ®Google Scholar
• Dong P, Ma L, Liu L, et al. CD86(+)/CD206(+), diametrically polarized tumor-associated macrophages, predict hepatocellular carcinoma patient prognosis. Int. J. Mol. Sci. 2016;17(3):320.
   PubMed Web of Science ®Google Scholar
• Zhang QB, Jia QA, Wang H, et al. High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis. BMC Cancer. 2016;16(1):016–2883. doi: 10.1186/s12885-016-2883-z.
   PubMed Web of Science ®Google Scholar
• Kuang DM, Zhao Q, Peng C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 2009;206(6):1327–1337. doi: 10.1084/jem.20082173.
   PubMed Web of Science ®Google Scholar
• Jia JB, Wang WQ, Sun HC, et al. High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist 2010;15(7):732–743. doi: 10.1634/theoncologist.2009-0170.
   PubMed Web of Science ®Google Scholar
• Hu ZQ, Zhou SL, Zhou ZJ, et al. Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection. Oncotarget 2016;7(32):51733–51746. doi: 10.18632/oncotarget.10104.
   PubMedGoogle Scholar
• Ren CX, Leng RX, Fan YG, et al. Intratumoral and peritumoral expression of CD68 and CD206 in hepatocellular carcinoma and their prognostic value. Oncol. Rep. 2017;38(2):886–898. doi: 10.3892/or.2017.5738.
   PubMed Web of Science ®Google Scholar
• Kono H, Fujii H, Furuya S, et al. Macrophage colony-stimulating factor expressed in non-cancer tissues provides predictive powers for recurrence in hepatocellular carcinoma. Wjg. 2016;22(39):8779–8789. doi: 10.3748/wjg.v22.i39.8779.
   PubMed Web of Science ®Google Scholar
• Zhu FY. 肿瘤相关性巨噬细胞标记物CD206在肝癌中的表达及其药物抑制研究[Dissertation].Chongqing, China:Chongqing Medical University; 2016.
   Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 2004; 4(1):71–78. doi: 10.1038/nrc1256.
   PubMed Web of Science ®Google Scholar
• Hughes R, Qian BZ, Rowan C, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 2015;75(17):3479–3491. doi: 10.1158/0008-5472.CAN-14-3587.
   PubMed Web of Science ®Google Scholar
• Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. JCO 2005;23(35):8959–8967. doi: 10.1200/JCO.2005.01.4910.
   PubMed Web of Science ®Google Scholar
• Hutterer GC, Pichler M, Chromecki TF, et al. Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology 2013;63(3):309–315. doi: 10.1111/his.12163.
   PubMed Web of Science ®Google Scholar
• Allavena P, Chieppa M, Bianchi G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin. Dev. Immunol. 2010;547179(10):9. doi: 10.1155/2010/547179.
   Google Scholar
• Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003;3(1):23–35. doi: 10.1038/nri978.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72(16):4165–4177. doi: 10.1158/0008-5472.CAN-11-2994.
   PubMed Web of Science ®Google Scholar
• Scodeller P, Simon-Gracia L, Kopanchuk S, et al. Precision targeting of tumor macrophages with a CD206 binding peptide. Sci. Rep. 2017;7(1):017–14709. doi: 10.1038/s41598-017-14709-x.
   PubMed Web of Science ®Google Scholar
• Falini B, Flenghi L, Pileri S, et al. PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am. J. Pathol. 1993;142(5):1359–1372.
   PubMed Web of Science ®Google Scholar